Blood plasma treatment has limited effect for sickest COVID patients
Treating critically ill COVID-19 patients with blood plasma from people who have fought off the disease has limited impact on patient outcomes.
The early findings, which are yet to be published, come from the REMAP-CAP study and show that treatment with convalescent plasma did not improve outcomes among patients requiring intensive care unit (ICU) support.
There was no evidence of harm associated with the administration of convalescent plasma, but investigators have paused enrollment of severely ill COVID-19 patients in ICU to this arm of REMAP-CAP study.
They explain the trial will continue to recruit hospitalised COVID-19 patients who are moderately unwell and are not requiring intensive care, to assess if less severely ill patients benefit from the treatment.
Professor Anthony Gordon, professor of anaesthesia and critical care at Imperial College London and an NIHR research professor, said: “I am glad REMAP-CAP has been able to provide important evidence about which patients might benefit from convalescent plasma.
“Although it is disappointing that all critically ill patients don’t appear to gain any benefit, this is still vitally important to know. Convalescent plasma is a precious resource, and we can now continue to focus on identifying exactly which patients might benefit the most from treatment – maybe people earlier in their illness or those with weak immune systems.”
Since 2007 Avensys have been a key player in the national picture of bio-medical equipment sale, repair, maintenance and training. Now owned by HERMED GmbH (part of the VAMED group), Avensys are part of the global medical infrastructure, able to offer a complete service for asset management including procurement, device maintenance, and training.